Skip to content
PharmaceuticalsHilden, NRWMDAX No programme known Updated on 07/10/2026

Job cuts at QIAGEN: severance pay and your rights

What employees need to know now: status of the cuts, severance practice and your rights.

Updated on 07/10/2026

Employees in GermanyEmployees DE

1,300

As of 2025

RevenueRevenue

$2.09bn

Group, financial year

HeadquartersHeadquarters

Hilden

North Rhine-Westphalia

Stock exchange listingStock exchange

MDAX

Industry Pharmaceuticals

Severance factorSeverance factor

0.7 to 1.2

Monthly salaries per year

The factor range is our estimate, not a commitment by the company. The actual severance pay depends on the individual case, in particular length of service, age and pay grade.

Severance pay at QIAGEN

Severance factor

0.7 to 1.2

Monthly salaries per year of employment

Editorial estimate
  1. 0
  2. 0,5
  3. 1,0
  4. 1,5
  5. 2,0

Vertical line: rule of thumb 0.5, no legal entitlement

Base amount

not known

Negotiating partner

Works council

Current arrangements

No job cuts programme has currently been announced at Qiagen. The diagnostics group is growing again: in the second quarter of 2025, group revenue rose by seven per cent to 534 million dollars, and the adjusted operating margin rose to 29.9 per cent. Even so, the workforce fell from 6,178 in 2022 to 5,654 at the end of 2025, a reduction of around 520 positions. This was achieved through efficiency gains and the discontinuation of individual product lines such as NeuMoDx and Dialunox, not through a formally announced programme. Qiagen employs around 1,300 people in Germany, mainly at the Hilden site. The negotiating partner is the works council (Betriebsrat).

Assessment of the severance factor

Because no programme is running, there is no social plan (Sozialplan) and there are no fixed rates. We derive a factor of 0.9, with a range of 0.7 to 1.2. This is supported by the high salary and qualification levels in diagnostics and research, the co-determination exercised by the works council at the Hilden site and, above all, the earnings position: an adjusted operating margin of around 29.5 per cent leaves room for manoeuvre. A dampening factor is that, without a collective framework, each departure is negotiated individually.

The factor is our own assessment, not a commitment from the company. Keep an eye on the takeover speculation: a change of ownership can alter structures and with them your own position. In individual cases, length of service, age and any special protection against dismissal count. Other circumstances of the individual case also play a role.

The factor is our estimate, derived from industry, region, co-determination and economic situation, and is not a commitment by the company. Length of service, age and special protection against dismissal can shift the result considerably.

Severance calculator

What you could be entitled to at QIAGEN

€
years

Possible severance pay

–

Special protection against dismissal?

€
Have your offer checked for free

Non-binding guidance based on the standard formula, not legal advice. There is only a right to severance pay in exceptional cases; the actual amount depends on the individual case, for example on age, maintenance obligations and whether the dismissal is valid. AbfindungsHero puts you in touch with employment law firms and does not provide legal services itself.

Headcount development

QIAGEN N.V., Germany

Source: annual reports

  1. 1,080 16
  2. 1,080 17
  3. 1,130 18
  4. 1,170 19
  5. 1,240 20
  6. 1,360 21
  7. 1,297 22
  8. 1,380 23
  9. 1,340 24
  10. 1,300 25

Scale starts at 630, not at zero.

Timeline of the job cuts

  1. 2023 Completed Restructuring and portfolio clean-up Qiagen discontinued loss-making product lines, including the NeuMoDx systems business and the subsidiary Dialunox; in the 2024 financial year, restructuring costs weighed heavily on earnings. No quantified job cuts programme was published. The global workforce fell from 6,178 employees at the end of 2022 to 5,654 at the end of 2025.

QIAGEN N.V.: job cuts, severance pay and employees' rights

No job cuts programme, but a shrinking workforce

No job cuts programme has currently been announced at Qiagen. The diagnostics group has put the post-Covid boom behind it and is growing again: in the second quarter of 2025, group revenue rose by seven per cent to 534 million dollars, and the adjusted operating margin climbed to 29.9 per cent. The company raised its annual guidance several times and expects to exceed its margin target set for 2028 ahead of schedule.

520 positions in three years

The workforce has nevertheless shrunk, from 6,178 employees in 2022 to 5,654 at the end of 2025. That is around 520 positions in three years. This was achieved through efficiency gains across the company and through the discontinuation of individual product lines, including the diagnostic systems NeuMoDx and Dialunox. A formally announced job cuts programme with a target number and timeframe, however, does not exist.

Hilden is the largest site

Qiagen employs around 1,300 people in Germany, mainly at the Hilden site near Düsseldorf. Legally, the group is a Dutch company headquartered in Venlo; Hilden is the largest operating site and the historic origin of the company.

When product lines are discontinued

Even without a programme, restructuring and individual departures occur, particularly when product lines are discontinued, as most recently with NeuMoDx and Dialunox. If an entire division is closed, the consequences for those affected differ from those of cuts within a division that continues to operate; this should be examined in each individual case.

Without a social plan, negotiation is what counts

Without a social plan in place, there is no fixed severance formula. The outcome therefore depends all the more on negotiation and on how robust the employer's justification is. The amount of severance pay (Abfindung) depends on length of service, age, salary, maintenance obligations and any severe disability. At Qiagen, one argument in negotiations is the economic situation: a company with an operating margin of almost 30 per cent is in a different position from a turnaround case.

How the group is doing in 2026

In 2025, revenue rose by six per cent to just under 2.09 billion dollars, and profit increased fivefold to 425 million dollars, after restructuring costs had weighed on the previous year; the adjusted operating margin was 29.5 per cent. 2026 has been bumpier: in April, Qiagen lowered its annual targets after a weak first quarter, and in the second quarter the group then exceeded its own forecast again with stable revenue of 535 million dollars. There is also ongoing takeover speculation, which management does not comment on. For employees, this is something to keep in mind: experience shows that a change of ownership alters structures faster than any savings programme.

Leaving Qiagen?

Without a programme there is no social plan, so everything depends on individual negotiation. In a company with an operating margin of almost 30 per cent, this is more of an opportunity than a disadvantage. An employment lawyer from our network will tell you in a free initial consultation what is realistic in your situation.

Affected by job cuts at QIAGEN?

Whether an offer is fair can only be judged on the specific case. An employment law firm will assess your situation free of charge.